The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets
First immunotherapy combination approved in the US for BCG-naïve high-risk NMIBC demonstrates a 32% reduction in the risk of disease recurrence, progression, or death
The approval is supported by results from the Phase 3 SWOG 1826 trial
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
